Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Tempus AI
Actym Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Elevation Oncology
Aminex Therapeutics, Inc.
Novartis
Ikena Oncology
CytomX Therapeutics
Fate Therapeutics
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Tocagen Inc.
Dartmouth-Hitchcock Medical Center
CureOne
sigma-tau i.f.r. S.p.A.
University of Pittsburgh
Celldex Therapeutics
University Health Network, Toronto
Masonic Cancer Center, University of Minnesota
Stanford University
Sir Mortimer B. Davis - Jewish General Hospital
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center